Anixa Biosciences, Inc.

twitter logo
Nasdaq: ANIX
  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Scientific Advisors
    • Breast Cancer Clinical Advisory Board
    • Cancer Business Advisory Board
  • Technologies
    • CAR-T
      • Introduction
      • Markets
      • Science
      • Collaborators
    • Cancer Vaccines
      • Introduction
      • Markets
      • Science
      • Collaborators
      • Breast Cancer Clinical Advisory Board
  • Pipeline
  • Investors
    • Overview
    • News Releases
    • The Future of Cancer Immunotherapy & Women’s Health
    • Events & Presentations
      • Events
      • Corporate Presentation
    • Stock Information
      • Quote
      • Charts
      • Historical Data
      • Analyst Coverage
    • SEC Filings
      • SEC Filings
    • Financial Reports
      • Annual Reports
      • Quarterly Reports
    • Corporate Governance
      • Governance Documents
      • Committee Charters
  • News
    • Press Releases
    • Anixa In The News
    • Publications
    • YouTube Channel
  • Contact Us

SEC Filings

Investors

Investors

  • Overview
  • News Releases
  • The Future of Cancer Immunotherapy & Women’s Health
  • Events & Presentations
    • Events
    • Corporate Presentation
  • Stock Info
    • Quote
    • Charts
    • Historical Data
    • Analyst Coverage
  • SEC Filings
  • Financial Reports
    • Annual Reports
    • Quarterly Reports
  • Governance
    • Governance Documents
    • Committee Charters
  • Investor Resources
    • Investor FAQs
    • Email Alerts
    • Fact Sheet
    • Contact IR
    • RSS News Feed
  • SEC Filings

  • Overview
Filter Filings:
Date Form Description Docs XBRL Pages
04/09/14 CORRESP A correspondence can be sent as a document with another submission type or can be sent as a separate submission. HTML PDF 5
04/07/14 UPLOAD SEC-generated letter PDF 2
03/31/14 S-3/A Registration statement for specified transactions by certain issuers
Related Documents
EX-1
EX-4
EX-4
EX-4
EX-4
EX-4
EX-4
EX-23
HTML PDF 101
03/31/14 8-K Current report filing HTML PDF 4
03/28/14 CORRESP A correspondence can be sent as a document with another submission type or can be sent as a separate submission. HTML PDF 2
03/24/14 4 Statement of changes in beneficial ownership of securities HTML PDF 2
03/24/14 4 Statement of changes in beneficial ownership of securities HTML PDF 2
03/17/14 10-Q Quarterly report pursuant to sections 13 or 15(d)
Related Documents
EX-10
EX-31
EX-31
EX-32
EX-32
HTML PDF XBRL Viewer XLS XBRL Files 74
03/13/14 CORRESP A correspondence can be sent as a document with another submission type or can be sent as a separate submission. HTML PDF 8
03/13/14 CORRESP A correspondence can be sent as a document with another submission type or can be sent as a separate submission. HTML PDF 3
RSS
  • << Previous
  • 1...
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • ...96
  • Next >>

Sign up for email Updates

Be The First to Receive Breaking News

Sign Up Now
Logo Itus
twitter logo

Latest News & Events

Feb 23, 2026

Anixa Biosciences Announces Dr. Jose Conejo-Garcia will Keynote the South Carolina Clinical & Translational Research Institute 2026 Retreat

Read More...
Feb 9, 2026

Anixa Biosciences Reports Encouraging Patient Survival Observations in Ovarian Cancer CAR-T Trial; Achieves Regulatory Approval Enabling Major Dose Escalation

Read More...
Feb 2, 2026

Anixa Biosciences Secures United States Adopted Names Council Approval of Non-Proprietary Name for its CAR-T Therapy, a Key Step Toward Future Commercialization

Read More...
Copyrights © 2026 Anixa Biosciences, Inc.. All Rights Reserved.
twitter logo Privacy Policy Terms of Use Disclaimer Sitemap